Merck & Co. pulled its application for EU clearance for Zolinza, a drug candidate for cutaneous T-cell lymphoma, according to the European Medicines Agency. The move was prompted by a provisional view from regulators that clinical data on the drug were insufficient. A Merck spokeswoman said the company plans to continue researching the drug's active ingredient, vorinostat, as a standalone or combination therapy.

Full Story:

Related Summaries